REZUROCK

Peak

belumosudil

NDAORALTABLETPriority Review
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13

Clinical Trials (5)

NCT07135973Phase 4Not Yet Recruiting

A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

Started Apr 2026
26 enrolled
Chronic Graft Versus Host Disease
NCT07116031Phase 2Recruiting

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

Started Dec 2025
37 enrolled
Chronic Graft Versus Host Disease
NCT05567406Phase 2Withdrawn

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Started Jun 2025
0
Chronic Graft Versus Host Disease
NCT06616415Phase 4Active Not Recruiting

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

Started Dec 2024
6 enrolled
Chronic Graft Versus Host Disease
NCT05922761Phase 2Recruiting

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Started May 2024
45 enrolled
Bronchiolitis Obliterans SyndromeBronchiolitis ObliteransLung Diseases+1 more

Loss of Exclusivity

LOE Date
Jul 14, 2042
199 months away
Patent Expiry
Jul 14, 2042
Exclusivity Expiry
Jul 16, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10183931
Oct 7, 2033
U-3246
10696660
Oct 7, 2033
U-3246
8357693
Jun 20, 2034
SubstanceProduct
U-4259
11311541
Apr 9, 2035
U-3369
12097202
Jul 14, 2042
U-4014